Page last updated: 2024-09-05

melagatran and Chronic Kidney Failure

melagatran has been researched along with Chronic Kidney Failure in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Attman, PO; Eriksson, UG; Fager, G; Frison, L; Johansson, S; Mulec, H; Samuelsson, O	1
Attman, PO; Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Ottosson, P; Samuelsson, O	1

Trials

2 trial(s) available for melagatran and Chronic Kidney Failure

Article	Year
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clinical pharmacokinetics, 2003, Volume: 42, Issue:8 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Glycine; Half-Life; Humans; Injections, Subcutaneous; International Normalized Ratio; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Thrombin; Time Factors	2003
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:9 Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; Glycine; Humans; International Normalized Ratio; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Uremia	2005

Article

Year

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.

Clinical pharmacokinetics, 2003, Volume: 42, Issue:8

Topics: Administration, Oral; Adult; Aged; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Glycine; Half-Life; Humans; Injections, Subcutaneous; International Normalized Ratio; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Thrombin; Time Factors

2003

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:9

Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; Glycine; Humans; International Normalized Ratio; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Uremia

2005